>
Switch to:

NovoCure PS Ratio

: 13.90 (As of Today)
View and export this data going back to 2015. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, NovoCure's share price is $72.07. NovoCure's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2021 was $5.19. Hence, NovoCure's PS Ratio for today is 13.90.

Good Sign:

NovoCure Ltd stock PS Ratio (=12.38) is close to 3-year low of 12.38

The historical rank and industry rank for NovoCure's PS Ratio or its related term are showing as below:

NAS:NVCR' s PS Ratio Range Over the Past 10 Years
Min: 5.78   Med: 17.79   Max: 68.11
Current: 12.38

5.78
68.11

During the past 8 years, NovoCure's highest PS Ratio was 68.11. The lowest was 5.78. And the median was 17.79.

NAS:NVCR's PS Ratio is ranked lower than
72% of the 754 Companies
in the Medical Devices & Instruments industry.

( Industry Median: 5.80 vs. NAS:NVCR: 12.38 )

NovoCure's Revenue per Sharefor the three months ended in Sep. 2021 was $1.29. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2021 was $5.19.

During the past 12 months, the average Revenue per Share Growth Rate of NovoCure was 22.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 31.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was 38.50% per year.

During the past 8 years, NovoCure's highest 3-Year average Revenue per Share Growth Rate was 110.30% per year. The lowest was 31.50% per year. And the median was 55.10% per year.

Back to Basics: PS Ratio


NovoCure PS Ratio Historical Data

The historical data trend for NovoCure's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
PS Ratio
Premium Member Only Premium Member Only Premium Member Only 8.10 10.11 12.40 23.32 38.11

NovoCure Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.26 38.11 26.95 43.34 22.41

Competitive Comparison

For the Medical Instruments & Supplies subindustry, NovoCure's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

NovoCure PS Ratio Distribution

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's PS Ratio distribution charts can be found below:

* The bar in red indicates where NovoCure's PS Ratio falls into.



NovoCure PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

NovoCure's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=72.07/5.185
=13.90

NovoCure's Share Price of today is $72.07.
NovoCure's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.19.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


NovoCure  (NAS:NVCR) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


NovoCure PS Ratio Related Terms

Thank you for viewing the detailed overview of NovoCure's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NovoCure Business Description

NovoCure logo
Industry
Traded in Other Exchanges
Address
Grenville Street, No. 4 The Forum, Second Floor, Saint Helier, JEY, JE2 4UF
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.
Executives
Weinberg Uri officer: Chief Science Officer NOVOCURE INC., 20 VALLEY STREAM PARKWAY SUITE 300 MALVERN PA 19355
Groenhuysen Wilhelmus Cm officer: Chief Operating Officer C/O NAVTEQ CORPORATION 222 MERCHANDISE MART STE 900 CHICAGO IL 60654
Danziger Asaf director, officer: Chief Executive Officer 5 NACHUM CHAT ST. TIRAT HACARMEL L3 5112302
Leung Gabriel director C/O PERNIX THERAPEUTICS HOLDINGS, INC. 10 NORTH PARK PLACE, SUITE 201 MORRISTOWN NJ 07960
Shah Pritesh officer: Chief Commercial Officer C/O NOVOCURE INC. 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355
Leonard Frank X officer: Chief Development Officer 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355
Cordova Ashley officer: Chief Financial Officer 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355
Madden Martin J. director C/O MICROBOT MEDICAL INC. 175 DERBY STREET 27/1 HINGHAM MA 02043
Benaim Ely officer: Chief Medical Officer C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE MD 20850
Doyle William F director, officer: Executive Chairman PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: DOYLE WILLIAM F a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Ambrogi Michael J. officer: Chief Operating Officer 195 COMMERCE WAY PORTSMOUTH NH 03801
Longsworth Todd Christopher officer: General Counsel NOVOCURE, 20 VALLEY STREAM PARKWAY SUITE 300 MALVERN PA 19355
Hilleman Jeryl L director C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025
Mccoy Sherilyn S director JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Hung David director C/O AXOVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018

NovoCure Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)